Physician profile
Stephen Lewen
NPI 1063481208
$471.80
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $86.72 · 2021: $79.56.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $250.18 | 2019 | |
| Eyepoint US, INC. | $43.59 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.56 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $30.61 | 2019-2020 | |
| Allergan, INC. | $29.12 | 2020 | |
| Ocular Therapeutix, INC. | $23.52 | 2019 | |
| Amarin Pharma, INC. | $21.05 | 2020 | |
| Alcon Vision LLC | $20.88 | 2020 | |
| Alimera Sciences, INC. | $19.29 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lewen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.